Avidin has developed a novel blood based diagnostic test that measures acquired T-cell immunity against the SARS-CoV2 coronavirus, following infection or immunization. Avidin is the first private company to offer such a test in Hungary.
Avidin’s Budapest site (Berlini u 47-49) was accredited as M3 authorization level of microbiological diagnostics laboratory.
The major focus of Avidin is to identify novel small molecules which can be further develop into novel drugs to treat CNS diseases and cancer. Avidin has widespread international scientific and industrial partnerships in drug discovery (medicinal chemistry, screen development, HTS genomics, and animal models). Besides in-house drug development programs, the company provides services and products in the segment of pharmaceutical research, in the preclinical phase of analyzing drug candidates (target and phenotypic-based hit identification, medicinal chemistry and lead optimization, proof of concept studies in vitro and in animal models, preclinical non-GLP toxicity and ADME/Tox studies) in cancer and CNS indications.
Avidin has a Medicinal Chemistry Department where new drug-like molecules, and novel drug-like and drug candidate molecules can be synthesized. Avidin runs an SPF-like animal house and capable of working with different cancer models in immune deficient animals. Avidin can also conduct toxicology measurements in rodents in acute and chronic studies. The company develops molecular biology-based novel diagnostic solutions as well. Among these, one is exceptionally successful the high-density nanoliter volume real-time PCR technology (100.000 QRT-PCR/week capacity). This technology was applied to screen the expression of toxicology-related genes and genes coding for cancer stem cell and activated stromal cell related genes.
In 2011 Avidin has specialized in single cell genomics, where the company enables digital measurements of mRNA, miRNA expression of individual cells with superior sensitivity and reproducibility. Our most advanced development is a novel quinoline analogue Q134 which bears with strong cytoprotective and nootropic properties for Alzheimer’s disease. After the initial in vitro and in vivo testing Q134 candidate successfully passed the preclinical testing and showed good results in Phase IA study.